Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

KEYNOTE-C11 : Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood

Systemic therapy | Blood / Myeloma / LymphomaHodgkin's Disease (Hodgkin's Lymphoma)

Trial Overview Read MoreRead more

This phase II trial is evaluating how effective a treatment of immunotherapy (pembrolizumab), followed by chemotherapy, and then followed with more immunotherapy is in people with newly diagnosed classical Hodgkin lymphoma.

This trial is treating patients with Hodgkin's lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)

Commercial Sponsor



This is a non-randomised trial with one experimental arm with several phases. All participants will first receive pembrolizumab administered intravenously (via IV) at a dose of 200mg on Day 1 of each 3-week cycle for 3 cycles. All participants will then undergo Positron Emission Tomography (PET) scans, and depending on these results, will receive one of two chemotherapy regimens. Some participants will receive AVD chemotherapy which involves doxorubicin in combination with vinblastine & dacarbazine, and other participants will receive escBEACOPP chemotherapy which involves etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, & prednisone. Following chemotherapy, all participants will receive more pembrolizumab as consolidation therapy. This time, pembrolizumab will be administered via IV at a dose of 400mg on Day 1 of each 6-week cycle for 4 cycles.

Recruiting Hospitals Read MoreRead more

Monash Health Haematology Research Unit
Miss Jeanette Gamgee
03 9594 4044

Not Recruiting Hospitals Read MoreRead more


PCCTU (Parkville Cancer Clinical Trials Unit) *
Felicity McLeay

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.